- Companies
- Science
Science Valuation, Funding & Investors
Science is valued at $1.5B as of March 2026.
Last Science valuation
$1.5B
Series C · Mar 2026
Last Science funding round
$230M
Series C · Mar 2026
Cumulative funding Science raised
$407M
across 4 funding rounds
Key investors in Science
Khosla Ventures
Y Combinator
Lightspeed Venture Partners
Quiet Capital
HOF Capital
Artis Ventures
About Science
Science is a clinical-stage medical technology company developing brain-computer interfaces for vision restoration, cognitive enhancement, and motor control. San Francisco-headquartered, it offers Axon neural probes, SciFi headstages, and Synapse protocols alongside implantable devices like PRIMA photovoltaic arrays for retinal diseases. The platform integrates neural recording, optogenetics, and software for modular neuroengineering applications.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$1.5B (Mar 2026)
Science Valuation
Science is currently valued at $1.5B, based on its Series C in March 2026.
The $230M round was led by Khosla Ventures and Lightspeed Venture Partners, with participation from Y Combinator, Julian Mann, HOF Capital, Quiet Capital and TCIM.
Science's valuation has moved from $1.5B at its undisclosed-stage round in June 2024 to $1.5B in March 2026, across 2 priced rounds.
Science valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2026 | Series C | $1.5B |
| Jun 2024 | Undisclosed stage | $1.5B |
Science Funding History
Science has raised a total of $407M across 4 funding rounds.
Science's first fundraising round was a $47M seed round in July 2021. The most recent completed round was a $230M Series C in March 2026.
Science funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2026 | Series C | Khosla Ventures (lead); Lightspeed Venture Partners (lead); Y Combinator; Julian Mann; HOF Capital; Quiet Capital; TCIM | $230M | $1.5B | - |
| Apr 2025 | Undisclosed stage | Khosla Ventures (lead); 885 Capital; Unbound Ventures | $104M | - | Science Corp., founded by Max Hodak (Neuralink co-founder), raised $104 million (of a planned $110 million) in a funding round led by Khosla Ventures around April 14-16, 2025. The Alameda, California-based biotech develops advanced brain and eye technology, including experimental retina implants for eye diseases and brain implant systems in early development, plus research equipment. Investors include Jai Mahtani, Khosla Ventures, Sudeep Ramnani, and Unbound Ventures, positioning Science as a Neuralink competitor in the growing brain technology sector. The company is actively hiring with the new capital. Science's devices remain experimental and not approved for human use, focusing on R&D rather than commercial traction metrics. The funding supports development in brain tech amid investor interest in AI-adjacent hardware like implants. The round aligns with Khosla Ventures' activity in April 2025, where it led 10 deals amid a slow VC market. Contextually, Khosla Ventures invests in deep tech and biotech, with this round exemplifying their focus on transformative neurotechnology. |
| Jun 2024 | Undisclosed stage | - | $26M | $1.5B | Science Corp., founded by Max Hodak (co-founder and former president of Neuralink), develops brain-computer interface technology aiming to be the first to bring a brain implant product to market. The company also launched Vessel, a new business line focused on organ preservation using miniaturized perfusion technology to enable transport on commercial flights or maintenance at home by patients. Science Corp. raised $230 million in a Series C funding round, bringing its total funding to $490 million. Investors included Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT (a nonprofit investment firm targeting government-applicable solutions). A source close to the startup indicated a post-money valuation of $1.5 billion for this round. The company employs 150 people and is pushing to get its brain implant to patients. |
| Jul 2021 | Seed | Serafund; Artis Ventures | $47M | - | - |
Who has invested in Science?
11 investors have backed Science across its funding rounds, including Khosla Ventures, Y Combinator, Lightspeed Venture Partners, Quiet Capital, HOF Capital and Artis Ventures.
Lead investors include Khosla Ventures and Lightspeed Venture Partners.
Science Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Apr 2025 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Apr 2025 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Lead | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
This data is available for Pro users. Sign up to see all 11 Science investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialScience Competitors
Science competitors include listed companies like BoneSupport and Alpha Tau Medical, and private ones like Cornerstone Robotics, ZD Medtech, CMR Surgical and Spirit AI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1B | - | ||
| Private | - | - | $900M | - | ||
| Private | - | - | $3B | - | ||
| Private | - | - | $1.5B | - | ||
| Publicly listed | $120M | $21M | $1.5B | 9.7x | ||
| Publicly listed | - | ($45M) | $1.4B | 2659.7x |
Science Public Comps
Science is still privately-owned, but its public comps include Savaria, Beijing Balance Medical, El.En. Group, BoneSupport, Shanghai MicroPort, Haier Biomedical, Nolato, Alpha Tau Medical, Alphatec Holdings and Nakanishi.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $655M | $113M | 2.5x | 2.3x | 14.3x | 11.2x | |||
| $92M | $37M | 15.9x | - | 40.0x | - | |||
| $680M | $96M | 1.9x | 2.1x | 13.3x | 11.1x | |||
| $120M | $21M | 11.8x | 9.7x | 67.1x | 36.2x | |||
| $201M | $108M | 6.1x | 5.6x | 11.4x | 10.6x | |||
| $347M | $54M | 3.6x | 3.4x | 23.7x | 22.2x | |||
| $965M | $161M | 1.4x | 1.4x | 8.7x | 8.3x | |||
| - | ($45M) | - | 2659.7x | (30.1x) | (26.5x) | |||
This data is available for Pro users. Sign up to see all Science competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Science
| When was Science founded? | Science was founded in 2021. |
| Where is Science headquartered? | Science is headquartered in San Francisco, CA, United States. |
| Is Science publicly listed? | No, Science is a private, VC-backed company. |
| What is Science's valuation? | Science was last valued at $1.5B in its Series C in March 2026. |
| How much funding has Science raised? | Science has raised $407M across 4 funding rounds. |
| What was Science's last funding round? | Science's last funding round was a $230M Series C in March 2026, led by Khosla Ventures and Lightspeed Venture Partners. |
| Who are Science's investors? | Science's investors include Khosla Ventures, Y Combinator, Serafund, 885 Capital, Julian Mann, Artis Ventures, HOF Capital, Lightspeed Venture Partners, Quiet Capital, Unbound Ventures and 1 other. |
| Which companies are comparable to Science? | Companies comparable to Science include Cornerstone Robotics, ZD Medtech, CMR Surgical, Spirit AI, BoneSupport and Alpha Tau Medical. |
See companies similar to Science
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




